괴사성 장염 시장 규모, 점유율, 성장 분석 : 치료법별, 중증도별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Necrotizing Enterocolitis Market size was valued at USD 3.6 Billion in 2024 and is poised to grow from USD 3.74 Billion in 2025 to USD 5.5 Billion by 2033, growing at a CAGR of 3.92% during the forecast period (2026-2033).

Market insights for necrotizing enterocolitis indicate robust growth driven by the rising prevalence of preterm births and heightened awareness of neonatal intestinal disorders. The adoption of advanced diagnostic technologies and improvements in microbiome-based therapies are contributing significantly to sales of treatments. The increasing use of biomarker-based diagnostics, probiotics, biologics, and minimally invasive surgical options further fuels market expansion. Investments in microbiome research, precision medicine, and early disease detection are enhancing clinical outcomes and reducing disease severity. Additionally, a growing focus on neonatal care and collaborative research is creating new market opportunities. However, challenges such as high treatment costs, limited approved therapies, stringent regulations, and complexities in diagnosis may impede market penetration in the foreseeable future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Necrotizing Enterocolitis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Necrotizing Enterocolitis Market Segments Analysis

Global necrotizing enterocolitis market is segmented by treatment type, severity stage, end user, and region. Based on treatment type, the market is segmented into bowel rest and decompression, antibiotic therapy, surgical intervention, and probiotic supplementation. Based on severity stage, the market is segmented into suspected NEC, Definite NEC, and advanced NEC. Based on end user, the market is segmented into neonatal intensive care units, pediatric hospitals, and specialty pediatric surgery centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Driver of the Global Necrotizing Enterocolitis Market

The expanding population of preterm infants necessitates heightened attention and specialized care in neonatal settings, amplifying the need for products aimed at preventing necrotizing enterocolitis. As medical professionals enhance their understanding of the disease and its serious implications, hospitals are increasingly adopting evidence-based protocols for management. Simultaneously, advocacy organizations emphasize the critical importance of early diagnosis and intervention. These dynamics create a significant drive for the development of innovative solutions and encourage manufacturers to enter the market, collectively contributing to robust growth in the global necrotizing enterocolitis landscape. This convergence of factors underscores the urgency and demand for effective care products.

Restraints in the Global Necrotizing Enterocolitis Market

The Global Necrotizing Enterocolitis market faces significant challenges due to the limited availability of neonatal intensive care units equipped with the specialized expertise and technology required for the early detection and treatment of NEC. This lack of accessible facilities hinders medical professionals from employing advanced diagnostic and therapeutic approaches. Consequently, the scarcity of such resources presents obstacles for product manufacturers, as the potential for market adoption in these regions remains low. Moreover, the difficulty in transferring preterm infants to higher-level care centers further exacerbates the issue, creating barriers that restrict market growth and innovation in NEC-related treatments.

Market Trends of the Global Necrotizing Enterocolitis Market

The Global Necrotizing Enterocolitis market is witnessing a significant trend toward precision diagnostics, driven by advancements in molecular profiling and point-of-care imaging technologies. These innovative tools enable early detection of the condition, allowing hospitals to implement effective monitoring programs and tailored nutritional interventions. Such improvements enhance patient care while optimizing resource utilization in neonatal intensive care units. As healthcare facilities worldwide increasingly adopt these technologies, the market is likely to experience robust growth, fostering a culture of proactive management and improving overall outcomes for vulnerable neonates affected by necrotizing enterocolitis.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Necrotizing Enterocolitis Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Bowel Rest and Decompression
• Antibiotic Therapy
• Surgical Intervention
• Probiotic Supplementation

Global Necrotizing Enterocolitis Market Size by Severity Stage & CAGR (2026-2033)

• Market Overview
• Suspected NEC
• Definite NEC
• Advanced NEC

Global Necrotizing Enterocolitis Market Size by End User & CAGR (2026-2033)

• Market Overview
• Neonatal Intensive Care Units
• Pediatric Hospitals
• Specialty Pediatric Surgery Centers

Global Necrotizing Enterocolitis Market Size & CAGR (2026-2033)

• North America (Treatment Type, Severity Stage, End User)
  • US
  • Canada
• Europe (Treatment Type, Severity Stage, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Severity Stage, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Severity Stage, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Severity Stage, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Mead Johnson Nutrition Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Nutrition International
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prolacta Bioscience Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Angel Biotechnology Holdings
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Infant Bacterial Therapeutics AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medela AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nestle Health Science SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danone Nutricia Research
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astarte Medical Partners Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B Braun Melsungen AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Perrigo Company plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Humanigen Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Deerfield Management Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Protaryx Biosciences Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomerica Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evolve BioSystems Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ByHeart Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gerber Products Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations